Metagenomi Therapeutics (MGX) Total Liabilities (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Total Liabilities data on file, last reported at $59.2 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $59.2 million, down 30.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.2 million (down 30.56% YoY), and the FY2025 annual result was $62.5 million, down 30.35% from the prior year.
• Total Liabilities fell to $59.2 million in Q1 2026 per MGX's latest filing, from $62.5 million in the prior quarter.
• Over five years, Total Liabilities peaked at $149.7 million in Q4 2023 and troughed at $119021.0 in Q3 2023.
• A 4-year average of $88.0 million and a median of $89.7 million in 2024 frame the typical range for Total Liabilities.
• On a YoY basis, Total Liabilities climbed as much as 86082.27% in 2024 and fell as far as 40.04% in 2024.
• A 4-year view of Total Liabilities shows it stood at $149.7 million in 2023, then slumped by 40.04% to $89.7 million in 2024, then sank by 30.35% to $62.5 million in 2025, then decreased by 5.34% to $59.2 million in 2026.
• Business Quant data shows MGX's Total Liabilities at $59.2 million in Q1 2026, $62.5 million in Q4 2025, and $69.5 million in Q3 2025.